Abstract Number: 2249 • ACR Convergence 2022
Impact of Interstitial Lung Disease on COVID-19 Severity Among Patients with Rheumatoid Arthritis: A Multicenter Comparative Study
Background/Purpose: Rheumatoid arthritis (RA) has been associated with severe COVID-19, but few studies have investigated outcomes in RA phenotypes such as interstitial lung disease (RA-ILD),…Abstract Number: 0191 • ACR Convergence 2022
Patient-reported Outcomes to Assess Dyspnea in Connective Tissue Diseases, Interstitial Lung Disease and Pulmonary Hypertension, a Systematic Literature Review of Measurement Properties
Background/Purpose: This COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN)-based systematic review aims to identify and summarize the quality of measurement properties of…Abstract Number: 0910 • ACR Convergence 2022
Rheumatoid Arthritis Associated Interstitial Lung Disease: The Role of Non-Criteria Autoantibodies
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation. RA-associated interstitial lung disease (ILD) is the most frequent and severe extra-articular…Abstract Number: 1231 • ACR Convergence 2022
[68Ga]- CPCR4 Trifluoroacetate PET/CT Imaging of Chemokine Receptor CXCR4- Expression in Systemic Sclerosis Related Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) in Systemic sclerosis (SSc) is a major contributor of morbidity and mortality. CXCR4/CXCL12 axis has been implicated in the pathogenesis…Abstract Number: 1855 • ACR Convergence 2022
Clinical Outcomes in an Observational Retrospective Cohort of Patients with Connective Tissue Disease-associated Interstitial Lung Disease (CTD-ILD) Who Taper Immunosuppressive Therapy
Background/Purpose: Patients with CTD-ILD are often treated with a combination of corticosteroids and steroid sparing agents to limit the progression of the inflammatory response in…Abstract Number: 2250 • ACR Convergence 2022
Genetic and Environmental Risk Factors in Rheumatoid Arthritis-Associated Interstitial Lung Disease
Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation of RA causing substantial morbidity and mortality. Genetic risk variants, such as the MUC5B rs35705950…Abstract Number: 0245 • ACR Convergence 2022
Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcomes in RA-ILD Patients Initiating a Biologic or Targeted-Synthetic DMARD
Background/Purpose: Patients with RA-associated interstitial lung disease (RA-ILD) suffer from substantial morbidity and premature mortality. The optimal use of biologic/tsDMARDs in this population is poorly…Abstract Number: 0920 • ACR Convergence 2022
Retention Rate and Safety of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients with Rheumatoid Arthritis Associated with Interstitial Lung Disease: Results from the KOBIO Registry
Background/Purpose: The aim was to evaluate long-term drug retention and safety of biologic (bDMARDs) or targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) and to identify…Abstract Number: 1246 • ACR Convergence 2022
Improving Radiologic Interpretation of Diffuse Lung Disease in Pediatric Rheumatologic (PR) Patients Using Trained Scoring with Semi-quantitative Chest Computed Tomography (CT) Analysis
Background/Purpose: We presented preliminary data in 2021 to support the feasibility of using a semi-quantitative chest CT scoring system (Pediatric Rheumatologic Diffuse Lung Disease Score…Abstract Number: 1857 • ACR Convergence 2022
Increasing Proportion of MDA-5 Associated Conditions in a Tertiary Myositis Centre Following Onset of the Covid-19 Pandemic
Background/Purpose: Anti-MDA5 dermatomyositis is a clinical subtype of DM that is strongly associated with a rapidly progressive phenotype of interstitial lung disease resulting in a…Abstract Number: 2251 • ACR Convergence 2022
Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib
Background/Purpose: Clinically significant interstitial lung disease (ILD) occurs in roughly 10% of patients with rheumatoid arthritis (RA). There are limited data on the pathogenesis of…Abstract Number: 0248 • ACR Convergence 2022
Monocyte Chemoattractant Protein-1, Vascular Cell Adhesion Protein-1 and Asymmetric Dimethylarginine as Potential Biomarkers of Interstitial Lung Disease Associated with RA
Background/Purpose: Interstitial lung disease (ILD) is one of the main comorbidities of patients with RA contributing to an increased mortality risk [1]. The pathogenesis of…Abstract Number: 1047 • ACR Convergence 2022
A Novel Prediction Tool for Progression of Systemic Sclerosis-Interstitial Lung Disease Despite Treatment with Immunosuppression
Background/Purpose: Systemic sclerosis-interstitial lung disease (SSc-ILD) is the leading cause of SSc-related death. While some patients respond favorably to treatment with immunosuppression, a subset of…Abstract Number: 1247 • ACR Convergence 2022
Lung Ultrasound in Patients with Connective Tissue Disease-associated Interstitial Lung Disease; Utility of Single Evaluation in Clinical Practice
Background/Purpose: Utility of lung ultrasound (LUS) in evaluation of interstitial lung disease (ILD) has recently attracted attention because of handiness and low invasiveness. The majority…Abstract Number: 1858 • ACR Convergence 2022
A Multi-center Clinical Cohort Study of Chinese Anti-synthetase Syndrome Patients
Background/Purpose: Based on the Chinese Rheumatology Data Center Inflammatory Myopathy Registry (CRDC-MYO), this study aimed to describe the baseline characteristics of a subgroup of patients…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 39
- Next Page »